Bellevue Group’s Ascendis Pharma A/S ASND Stock Holding History

Bellevue Group’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-536	Closed	-$123K	–	151
2026 Q1	$123K	Sell	536 -23,794	-98%	-$5.33M	﹤0.01%	136
2025 Q4	$5.19M	Sell	24,330 -573	-2%	-$118K	0.1%	74
2025 Q3	$4.95M	Sell	24,903 -3,752	-13%	-$700K	0.1%	75
2025 Q2	$4.95M	Buy	28,655 +26,755	+1,408%	+$4.36M	0.11%	82
2025 Q1	$296K	Sell	1,900 -600	-24%	-$85.7K	0.01%	128
2024 Q4	$344K	Buy	+2,500	New	+$329K	0.01%	130
2021 Q2	–	Sell	-15,500	Closed	-$2M	–	215
2021 Q1	$2M	Hold	15,500	–	–	0.02%	143
2020 Q4	$2.58M	Hold	15,500	–	–	0.03%	140
2020 Q3	$2.39M	Buy	15,500 +2,200	+17%	+$316K	0.03%	141
2020 Q2	$1.97M	Buy	13,300 +1,400	+12%	+$192K	0.03%	135
2020 Q1	$1.34M	Buy	+11,900	New	+$1.55M	0.03%	136
2019 Q4	–	Sell	-13,600	Closed	-$1.31M	–	217
2019 Q3	$1.31M	Sell	13,600 -4,600	-25%	-$513K	0.02%	133
2019 Q2	$2.1M	Hold	18,200	–	–	0.04%	129
2019 Q1	$2.14M	Buy	+18,200	New	+$1.59M	0.12%	104

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Bellevue Group's ASND Position: Q2 2026 in Review

Bellevue Group sold out of Ascendis Pharma A/S (ASND) in Q2 2026, closing a stake of 536 shares — an estimated $123K sold.

Bellevue Group first reported a position in ASND in Q1 2019 and held it in 14 quarters. The position peaked at $5.19M in Q4 2025. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Bellevue Group reported no remaining Ascendis Pharma A/S position as of Q2 2026 after selling out during the quarter.
Bellevue Group sold 536 Ascendis Pharma A/S shares in Q2 2026, an estimated $123K.
Bellevue Group first reported a position in Ascendis Pharma A/S in Q1 2019 and held it in 14 quarters.
Bellevue Group's Ascendis Pharma A/S position peaked at $5.19M in Q4 2025.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.